These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 17712819)

  • 21. Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.
    Marsot A; Audebert C; Attolini L; Lacarelle B; Micallef J; Blin O
    J Pharm Pharm Sci; 2016; 19(3):411-422. PubMed ID: 27806250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe toxicity following synthetic cannabinoid ingestion.
    Lapoint J; James LP; Moran CL; Nelson LS; Hoffman RS; Moran JH
    Clin Toxicol (Phila); 2011 Oct; 49(8):760-4. PubMed ID: 21970775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of cannabinoids.
    Grotenhermen F
    Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Passive exposure in detection of low blood and urine cannabinoid concentrations].
    Skopp G; Pötsch L
    Arch Kriminol; 2001; 207(5-6):137-47. PubMed ID: 11508050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a high-performance liquid chromatography method for the evaluation of niflumic acid cross-reactivity of two commercial immunoassays for cannabinoids in urine.
    Kovatsi L; Pouliopoulos A; Papadaki A; Samanidou V; Tsoukali H
    J Anal Toxicol; 2010 May; 34(4):229-32. PubMed ID: 20465870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of selected synthetic cannabinoids and their metabolites by micellar electrokinetic chromatography--mass spectrometry employing perfluoroheptanoic acid-based micellar phase.
    Švidrnoch M; Přibylka A; Maier V
    Talanta; 2016 Apr; 150():568-76. PubMed ID: 26838444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint.
    Toennes SW; Ramaekers JG; Theunissen EL; Moeller MR; Kauert GF
    J Anal Toxicol; 2008 Sep; 32(7):470-7. PubMed ID: 18713514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cannabis and cannabinoids as drugs].
    Khiabani HZ; Mørland J
    Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive inhalation of cannabis smoke.
    Law B; Mason PA; Moffat AC; King LJ; Marks V
    J Pharm Pharmacol; 1984 Sep; 36(9):578-81. PubMed ID: 6149279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multitarget cannabinoids as novel strategy for Alzheimer disease.
    González-Naranjo P; Campillo NE; Pérez C; Páez JA
    Curr Alzheimer Res; 2013 Mar; 10(3):229-39. PubMed ID: 23369066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoids in postmortem toxicology.
    Lemos NP; Ingle EA
    J Anal Toxicol; 2011 Sep; 35(7):394-401. PubMed ID: 21871147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex differences in behavioral effects of cannabinoids.
    Craft RM
    Life Sci; 2005 Sep; 77(20):2471-8. PubMed ID: 15958268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid analysis of synthetic cannabinoids using a miniature mass spectrometer with ambient ionization capability.
    Ma Q; Bai H; Li W; Wang C; Cooks RG; Ouyang Z
    Talanta; 2015 Sep; 142():190-6. PubMed ID: 26003711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cannabis: toxicokinetic focus and methodology of urinary screening].
    Pélissier AL; Léonetti G; Villani P; Cianfarani F; Botta A
    Therapie; 1997; 52(3):213-8. PubMed ID: 9366105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual.
    Pichini S; Mannocchi G; Gottardi M; Pérez-Acevedo AP; Poyatos L; Papaseit E; Pérez-Mañá C; Farré M; Pacifici R; Busardò FP
    Talanta; 2020 Mar; 209():120537. PubMed ID: 31892011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.
    Castaneto MS; Scheidweiler KB; Gandhi A; Wohlfarth A; Klette KL; Martin TM; Huestis MA
    Drug Test Anal; 2015 Jun; 7(6):483-93. PubMed ID: 25231213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and characterization of the new synthetic cannabinoid APP-BINACA in forensic casework.
    Krotulski AJ; Mohr ALA; Diamond FX; Logan BK
    Drug Test Anal; 2020 Jan; 12(1):136-144. PubMed ID: 31788963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and disposition of cannabinoids.
    Chiang CN; Rapaka RS
    NIDA Res Monogr; 1987; 79():173-88. PubMed ID: 2830536
    [No Abstract]   [Full Text] [Related]  

  • 40. The detection and quantification of cannabinoids in blood and urine by RIA, HPLC/RIA and GC/MS.
    Law B; Williams PL; Moffat AC
    Vet Hum Toxicol; 1979; 21 Suppl():144-7. PubMed ID: 505941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.